19:59 , Jul 27, 2018 |  BioCentury  |  Finance

Manipulating microglia

Alector Inc.’s $133 million series E round provides enough runway for the immuno-neurology and immuno-oncology company to take at least five programs into the clinic in the next two years. Participants in the untranched round,...
18:11 , Jul 27, 2018 |  BC Week In Review  |  Financial News

Alector raises $133M series E

Immuno-neurology and immuno-oncology company Alector Inc. (South San Francisco, Calif.) raised $133 million in a series E round. Participants included new investors Deerfield Management, Federated Kaufmann Fund, Section 32, Euclidean Capital, Foresite Capital, Lilly Asia Ventures,...
23:57 , Jul 26, 2018 |  BC Innovations  |  Targets & Mechanisms

PureTech plumbs the brain

PureTech Health plc is backing a new way of thinking about Alzheimer’s disease that positions it primarily as a problem of poor drainage, building on the recent discovery of lymphatic vessels in the brain by...
11:02 , Jul 25, 2018 |  BC Extra  |  Financial News

Alector raises $133M series E

Immuno-neurology and immuno-oncology company Alector Inc. (South San Francisco, Calif.) raised $133 million in a series E round. Participants included new investors Deerfield Management, Federated Kaufmann Fund, Section 32, Euclidean Capital, Foresite Capital, Lilly Asia Ventures,...
23:13 , Jan 25, 2018 |  BC Innovations  |  Strategy

Takeda rides Denali’s ATV

In its deal with Denali, Takeda has not only boosted its CNS pipeline, but also gained access to a delivery technology that could open the door to a host of CNS targets only druggable with...
03:19 , Jan 19, 2018 |  BC Innovations  |  Strategy

After amyloid

As the Alzheimer’s field is slowly taking on the search for new targets outside of the β amyloid and tau hypotheses, researchers are ramping up exploration of new pathways and looking to the disease’s genetics...
18:58 , Oct 27, 2017 |  BC Week In Review  |  Company News

Alector, AbbVie in Alzheimer's deal

Alector LLC (San Francisco, Calif.) and AbbVie Inc. (NYSE:ABBV) partnered to discover and develop immuno-neurology therapies against undisclosed targets to treat Alzheimer's disease. Alector will receive $205 million up front and an AbbVie investment of up...
11:33 , Oct 24, 2017 |  BC Extra  |  Company News

Alector, AbbVie in Alzheimer’s deal

Alector LLC (San Francisco, Calif.) and AbbVie Inc. (NYSE:ABBV) partnered to discover and develop immuno-neurology therapies against undisclosed targets to treat Alzheimer's disease. Alector will receive $205 million up front and an AbbVie investment of up...
19:08 , Mar 23, 2017 |  BC Innovations  |  Finance

Biology on the mind

Less than a year and a half after its launch, the Dementia Discovery Fund has spawned four new companies and invested almost 10% of the roughly $100 million it raised in 2015. With a goal...
08:00 , Jan 11, 2016 |  BC Week In Review  |  Financial News

Alector completes venture financing

Alector LLC, San Francisco, Calif.   Business: Antibodies, Neurology   Date completed: 2016-01-07   Type: Venture financing   Raised: $29.5 million   Investors: Dementia Discovery Fund; Amgen Ventures; AbbVie Inc.; Merck Research Labs Ventures Fund; OrbiMed Advisors; Polaris Partners;...